Merck & Co., Inc. $MRK Stake Lessened by Mediolanum International Funds Ltd

Mediolanum International Funds Ltd lessened its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 43.9% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 513,788 shares of the company’s stock after selling 402,061 shares during the quarter. Merck & Co., Inc. comprises about 0.6% of Mediolanum International Funds Ltd’s investment portfolio, making the stock its 29th biggest holding. Mediolanum International Funds Ltd’s holdings in Merck & Co., Inc. were worth $60,678,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Kingdom Financial Group LLC. bought a new position in Merck & Co., Inc. during the 4th quarter valued at $25,000. Abound Financial LLC bought a new stake in shares of Merck & Co., Inc. in the 4th quarter worth $26,000. Prosperity Bancshares Inc bought a new stake in shares of Merck & Co., Inc. in the 4th quarter worth $26,000. High Note Wealth LLC lifted its holdings in shares of Merck & Co., Inc. by 58.9% in the fourth quarter. High Note Wealth LLC now owns 294 shares of the company’s stock valued at $31,000 after buying an additional 109 shares during the period. Finally, IFC & Insurance Marketing Inc. acquired a new stake in shares of Merck & Co., Inc. in the fourth quarter valued at $31,000. Institutional investors own 76.07% of the company’s stock.

Trending Headlines about Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: The FDA approval of LIPFENDRA gives Merck its first oral PCSK9 inhibitor, opening a new revenue stream in cardiovascular care and strengthening its non-oncology portfolio. Reuters article on FDA approval
• Positive Sentiment: Analysts highlighted continued oncology pipeline progress, including FDA acceptance of multiple regulatory filings and Merck’s broader effort to offset the eventual 2028 Keytruda patent cliff. Seeking Alpha article on pipeline expansion
• Neutral Sentiment: Coverage also noted that Lipfendra’s launch is expected soon and that the drug could become a major product over time, though sales will depend on uptake, pricing, and competition from existing cholesterol therapies. Zacks article on Lipfendra launch
• Neutral Sentiment: There was also a rumor that Merck may be in a takeover battle for genomics company Personalis, but this appears speculative and is not confirmed. Yahoo Finance article on Personalis rumor

Merck & Co., Inc. Price Performance

Shares of NYSE:MRK opened at $127.47 on Friday. The company has a market capitalization of $314.83 billion, a PE ratio of 35.91, a price-to-earnings-growth ratio of 4.39 and a beta of 0.19. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.06 and a current ratio of 1.30. The stock has a fifty day moving average of $120.11 and a 200-day moving average of $116.94. Merck & Co., Inc. has a one year low of $76.66 and a one year high of $131.74.

Merck & Co., Inc. (NYSE:MRK) last issued its earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.47) by $0.19. The business had revenue of $16.29 billion for the quarter, compared to analysts’ expectations of $15.85 billion. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The company’s quarterly revenue was up 4.9% on a year-over-year basis. During the same period in the previous year, the firm posted $2.22 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. As a group, equities analysts anticipate that Merck & Co., Inc. will post 2.76 EPS for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, July 8th. Investors of record on Monday, June 15th were given a $0.85 dividend. The ex-dividend date was Monday, June 15th. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.7%. Merck & Co., Inc.’s dividend payout ratio (DPR) is 95.77%.

Analyst Ratings Changes

A number of research firms recently issued reports on MRK. Weiss Ratings lowered Merck & Co., Inc. from a “hold (c+)” rating to a “hold (c)” rating in a report on Friday, May 15th. Guggenheim upped their price target on shares of Merck & Co., Inc. from $140.00 to $145.00 and gave the company a “buy” rating in a report on Monday, July 13th. Royal Bank Of Canada restated an “outperform” rating and set a $142.00 price objective on shares of Merck & Co., Inc. in a research report on Wednesday, July 8th. Scotiabank lifted their price objective on shares of Merck & Co., Inc. from $136.00 to $155.00 and gave the stock a “sector outperform” rating in a research note on Tuesday, June 30th. Finally, CICC Research started coverage on shares of Merck & Co., Inc. in a research note on Wednesday, June 24th. They issued an “outperform” rating and a $138.00 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and seven have issued a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $133.94.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.